Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

CDK4/6 Inhibitors Continue to Revolutionize ER+ Breast Cancer Care

Caroline Seymour
Published: Monday, Jul 16, 2018

Yelena Novik, MD

Yelena Novik, MD

FDA approvals of the 3 novel CDK4/6 inhibitors– palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) have given oncologists a tool in their armamentarium against metastatic estrogen receptor (ER)-positive breast cancer, according to Yelena Novik, MD.

State of the Science Summit™ on Breast Cancer, Novik, associate professor, NYU Langone’s Perlmutter Cancer Center, discussed the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.

OncLive: Please provide an overview of your presentation.

Novik: We discussed overcoming hormone resistance in the treatment of [patients with] advanced and metastatic breast cancer. Over the last few years, we've been lucky to have access to new targeted agents of cell-cycle inhibitors. Currently, we have 3 FDA-approved agents–palbociclib, ribociclib, and abemaciclib. They have been shown in randomized controlled studies to be superior to hormonal agents in improving PFS, as well as responses in women with advanced breast cancer.

I discussed the PALOMA, MONALEESA, and MONARCH randomized studies. PALOMA-2 compared palbociclib versus placebo in combination with letrozole. MONALEESA-3 combined ribociclib versus placebo. MONARCH 2 examined abemaciclib versus placebo in both the first-line and second-line treatment of metastatic breast cancer with fulvestrant. These drugs work through the D1 cycle mechanism to significantly improve PFS in advanced breast cancer. We are very lucky to be able to offer these options to our patients.

What is the impact of the MONALEESA-7 trial?

Most of the trials in advanced breast cancer specifically target women who are menopausal or postmenopausal. It's much more difficult to conduct trials that specifically target premenopausal women. The MONALEESA-7 trial was directed to premenopausal women.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication